Callisto Pharma To Discuss Key Results Of Its Anticancer Drug ...

(RTTNews) - Wednesday early morning, Callisto Pharmaceuticals Inc. (KAL PowerRating), a developer of new drug treatments for cancer, said that it would discuss its drug development pipeline and key results of recent clinical and research studies, with investment professionals at the Equities 55th Anniversary Conference, on April 21, at Yale Club in New York.

According to the company, two of its anticancer drug candidates are undergoing Phase I/IIa human clinical trials at many leading cancer research institutions. One of them is L-Annamycin, indicated for treatment of relapsed and refractory acute leukemias. The Company said that it is also running two clinical programs with its second drug candidate Atiprimod. One trial involves patients with multiple myeloma, and the second trial involves advanced cancer patients.

In addition to these trials, the company had recently announced its plans to initiate another Phase I/II clinical trial of Atiprimod specifically in carcinoid patients. The company initiated this study based on response in a patient with carcinoid cancer and encouraging data observed in the case of other patients suffering from the same cancer. Dr. Gary Jacob, CEO, would also discuss the company's proprietary drug candidate Guanilib, indicated for gastrointestinal diseases, at the conference. Guanilib, an orally deliverable compound, is designed to mimic a naturally-occurring hormone called uroguanylin, deficiency of which is supposed to be one of the primary reasons for the formation of polyps and inflammatory disorders like ulcerative colitis. KAL closed Tuesday's regular trading session at $1.31, down $0.02 on a volume of 119,900 shares.

Copyright(c) 2006 RealTimeTraders.com, Inc. All Rights Reserved

About TradingMarkets What Customers Are Saying

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

This is cache, read story here